Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

- Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for... | May 15, 2023

Related Keywords

Spain ,United States ,Boston ,Massachusetts ,American ,Spanish ,Chris Railey ,Julie Seidel ,Matthew Kapusta ,Laurence Reid ,Exchange Commission ,European Medicines Agency ,Bridge Communications ,Twitter ,Company Phase ,Decibel Therapeutics Inc ,European Union ,Stern Ir Inc ,Committee On Orphan Medicinal Products ,Good Laboratory Practices ,Spanish Agency Of Medicines ,Regeneron Pharmaceuticals ,European Commission ,Hearing Loss Program ,Globenewswire Inc ,Drug Administration ,Development Expenses ,American Society Of Gene ,American Society Of Clinical Oncology ,Healthcare Products Regulatory Agency ,Association For Research ,Chief Executive Officer ,Upcoming Milestones ,Monogenic Hearing ,Received European Orphan Drug Designation ,Medical Devices ,Clinical Trial Applications ,Investigational New Drug ,Medicines Agency ,Orphan Medicinal ,Presentations Related ,Annual Meeting ,Presented New Non Clinical Safety Data ,Midwinter Meeting ,Product Candidate ,Related Hearing Loss Program ,Initiated Manufacturing Activities ,Enabling Studies ,Clinical Trial Data ,Clinical Oncology ,Directors Update ,Administrative Expenses ,Private Securities Litigation Reform Act ,Quarterly Report ,Consolidated Balance Sheet Data ,Consolidated Statement ,Decibel Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Nitiated ,Lobal ,Hase ,Nose ,Escalation ,Linical ,Trial ,F ,Head ,Gene ,Therapy ,Product ,Nnounced ,Approval ,Rom ,The ,Phra ,End ,Temps ,Or ,Tas Dbtx Us24343r1068 ,